Leerink Partnrs Has Bearish Outlook for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn ($3.80) per share for the year, down from their previous forecast of ($2.85). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($5.00) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($2.45) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) EPS.

A number of other brokerages also recently commented on XENE. Raymond James reaffirmed an “outperform” rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $40.45 on Friday. The stock’s 50 day moving average is $40.27 and its 200-day moving average is $40.79. Xenon Pharmaceuticals has a twelve month low of $35.53 and a twelve month high of $50.99.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Loomis Sayles & Co. L P grew its position in shares of Xenon Pharmaceuticals by 7.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company’s stock worth $27,843,000 after buying an additional 46,964 shares during the period. Vestal Point Capital LP grew its holdings in Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock worth $32,480,000 after purchasing an additional 300,000 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Xenon Pharmaceuticals by 4.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company’s stock valued at $17,287,000 after purchasing an additional 17,953 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after purchasing an additional 905,129 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 13,903 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.40. This represents a 41.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gary Patou sold 4,891 shares of Xenon Pharmaceuticals stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the completion of the transaction, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,383 shares of company stock worth $2,535,891 in the last quarter. 5.52% of the stock is owned by insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.